Medical devices to be treated as drugs

Published - February 09, 2019 01:20 am IST - NEW DELHI

From April 1, 2020, all implantable devices, CT Scan, PET and MRI equipment, defibrillators, dialysis machines and bone marrow separators will be treated as drugs for human beings. File

From April 1, 2020, all implantable devices, CT Scan, PET and MRI equipment, defibrillators, dialysis machines and bone marrow separators will be treated as drugs for human beings. File

The Centre in a notification on Friday said that medical devices — all implantable devices, CT Scan, PET and MRI equipment, defibrillators, dialysis machines and bone marrow separators — will be treated as drugs for human beings with effect from April 1, 2020.

The decision was taken in consultation with the Drugs Technical Advisory Board.

‘Implementation delay’

“Majority of medical devices are completely unregulated in India. With this move, all implantable devices and some diagnostic equipment will be brought into the regulatory framework which is important from a patient safety perspective. We welcome this step. However we are disappointed about the delay with which the notification takes effect,” said Malini Aisola of All India Drug Action Network.

She added that it also sends mixed messages because the Government is deliberating a roadmap for brining new and separate regulatory framework for devices.

Meanwhile after the first stakeholders meeting of The Central Drugs Standard Control Organisation(CDSCO) here on Friday on roadmap for regulation of medical devices with stakeholders of the industry Pavan Choudary,chairman,Medical Technology Assocition of India said: ““Since substantial expertise and experience lie with CDSCO in regulating this sector, the medical device sector feels that it would be best that the authorship of the agenda and the road map stays with them. This would also prevent any duplication.”

He added: “As this is a technology and capital intensive sector, growth in indigenous manufacturing is a function of maturity of technological ecosystem, ability to attract capital particularly from legacy investors, market attractiveness & ease of doing business. We, therefore think, that to judge the quality of regulations by the yardstick of how much import substitution these have delivered is unfair. A time bound regulatory roadmap was discussed,” said

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.